GLP-1 Drugs Like Semaglutide Quietly Deplete Key Nutrients Over Time
A review of 480,000+ adults finds GLP-1 receptor agonist users face rising deficits in vitamin D, iron, calcium, and B vitamins.
50 articles
A review of 480,000+ adults finds GLP-1 receptor agonist users face rising deficits in vitamin D, iron, calcium, and B vitamins.
A novel bone-mimicking scaffold delivering low-dose rhBMP-2 achieved complete fracture union in 4 months in a medically complex elderly patient.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
Experts say the next era of obesity care pairs GLP-1 medications with precision medicine, endoscopic procedures, and surgery for lasting results.
GLP-1 receptor agonists used for obesity may deliver an unexpected reproductive benefit: higher testosterone and better sperm.
A large records review finds semaglutide users had significantly fewer bone fractures than those on other diabetes or weight-loss drugs.
GLP-1 receptor agonists used for weight loss may also restore male reproductive hormones and improve sperm parameters.
OrsoBio's mitochondrial drug TLC-6740 added 4.5% more weight loss on top of tirzepatide in a Phase 2a trial, with bonus metabolic and cognitive benefits.
Preclinical data shows MS-001 deepens weight loss with semaglutide, preserves muscle, and curbs regain after stopping GLP-1 drugs.
A large cohort study finds GLP-1 receptor agonists slash obesity-linked cancer risk by 41%, with tirzepatide outperforming semaglutide dramatically.
OrsoBio's oral TLC-6740 paired with tirzepatide boosted weight loss by an extra 4.5% in 24 weeks, with gains in insulin sensitivity and liver health.
A once-daily pill and weekly injection show promising weight loss results, rivaling existing GLP-1 therapies in early clinical testing.